Company & Sponsor Intelligence

Eisai Inc.

Evidence-linked intelligence derived from the current NeuroRisk clinical research corpus. Coverage reflects indexed source data and is not a claim of complete company activity.

Request enterprise analysis →

Indexed trials25

Recruiting5

Completed14

Countries4

Therapeutic footprint

alzheimersepilepsyneurodevelopmental_otherpain_neuropathyparkinsonssleep_disordersstroke

Indexed studies

NCT01240187A Study to Demonstrate Bioequivalence Between 6 x 2 mg Tablets of Perampanel and a Single 12 mg Tablet of Perampanel in Healthy Subjects
epilepsy · United KingdomPHASE1

NCT01209858A Study to Investigate the Potential Pharmacokinetic Interaction of Perampanel With Oral Contraceptives in Healthy Female Subjects
epilepsy · United KingdomPHASE1

NCT00056576Dose Response Study of Zonegran in Patients With Newly Diagnosed Epilepsy
epilepsy · United StatesPHASE3

NCT07493265A Study to Evaluate the Efficacy and Safety of E2086 in Adults With Narcolepsy
sleep_disorders · United StatesPHASE2

NCT00165737Donepezil Hydrochloride (E2020) in Dementia Associated With Cerebrovascular Disease
stroke · United StatesPHASE3

NCT00566254Efficacy and Safety of Adjunctive Zonisamide in Paediatric Partial Onset Seizures (CATZ Study)
epilepsy · BelgiumPHASE3

NCT03686033A Study to Evaluate the Pharmacodynamic Activity of E2082 in Adult Participants With Photosensitive Epilepsy
epilepsy · United StatesPHASE2

NCT01221259A Randomized, Double-blind, Placebo-controlled, Sequential Ascending, Single-dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2212 in Healthy Subjects
alzheimers · United StatesPHASE1

NCT01327859Safety, Tolerability, and Efficacy of Donepezil (Aricept) in Parkinson' s Disease (PD) Patients With Dementia
parkinsons · United KingdomPHASE3

NCT03778424An Extended Access Program (EAP) for Participants Who Have Completed Rufinamide Study E2080-G000-303
epilepsy · PolandAVAILABLE

NCT00711204Evaluating The Impact Of Donepezil Hydrochloride (Aricept) On Behavioral And Psychological Symptoms In Patients With Severe Alzheimer's Disease
alzheimers · United StatesPHASE4

NCT04468659AHEAD 3-45 Study: A Study to Evaluate Efficacy and Safety of Treatment With Lecanemab in Participants With Preclinical Alzheimer's Disease and Elevated Amyloid and Also in Participants With Early Preclinical Alzheimer's Disease and Intermediate Amyloid
alzheimers · United StatesPHASE3

Intelligence layer updated: 2026-10-29 06:17:44.639239+00:00

Enterprise intelligence

Compare sponsor activity, recruiting momentum, therapeutic exposure, geography and connected research signals across the neuroscience ecosystem.

Request comparative intelligence →